Organization
Gustave Roussy, Cancer Campus, Grand Paris
45 clinical trials
Clinical trial
Study Evaluating Near-infrared Imaging Coupled With Indocyanine Green for Intraoperative Control of Resection Margins in ENT SurgeryStatus: Recruiting, Estimated PCD: 2026-05-01
Clinical trial
Phase II Trial of Nivolumab for Pediatric and Adult Relapsing/Refractory Anaplastic Large Cell Lymphoma, for Evaluation of Response in Patients With Progressive Disease Cohort 1 or as Consolidative Immunotherapy in Patients in Complete Remission After Relapse Cohort 2Status: Recruiting, Estimated PCD: 2025-04-01
Clinical trial
Thromboprophylaxis in Good and Intermediate Prognosis Advanced Germ Cell TumorsStatus: Recruiting, Estimated PCD: 2028-02-01
Clinical trial
A Phase I/II Study Evaluating the Safety and Clinical Activity of Anti-PDL1 (Durvalumab [MEDI4736]) + Anti CTLA-4 (Tremelimumab) Antibodies Administrated in Combination With Stereotactic Body Radiotherapy (SBRT) in Patients With Metastatic Squamous Cell Carcinoma of Head and Neck, Lung, Oesophageus, Cervix, Vagina,Vulva or AnusStatus: Active (not recruiting), Estimated PCD: 2024-06-01
Clinical trial
Efficacy and Feasibility of Pasireotide to Reduce Clinically Relevant Digestive Leakage After Complete Cytoreductive Surgery (CRS) Plus Hyperthermic Intra-Peritoneal Chemotherapy (HIPEC) for Peritoneal Carcinomatosis - a Phase II Randomized Multicentric TrialStatus: Terminated, Estimated PCD: 2024-02-07
Clinical trial
Multicentric Randomized Phase I/IIa Trial of the Safety and Immunogenicity of a Therapeutic Anti-HPV DC Targeting Vaccine in Patients With Human Papillomavirus (HPV)-Positive Oropharyngeal CancerStatus: Recruiting, Estimated PCD: 2025-08-01
Clinical trial
A Single-arm Phase 2 Study of Atezolizumab as Induction Therapy in Stage IB-IIIA Non N2 Resectable and Untreated Non-small Cell Lung Cancer (NSCLC)Status: Completed, Estimated PCD: 2023-03-01
Clinical trial
First Line Randomised Study Platform to Optimize Treatment in Patients With Metastatic Renal Cell CarcinomaStatus: Recruiting, Estimated PCD: 2032-05-05
Clinical trial
Multicentric Randomized Phase III Trial Comparing Methotrexate and Cetuximab in First-line Treatment of Recurrent and/or Metastatic Squamous Cell Head and Neck Cancer in Elderly Unfit Patients According to Geriatric EvaluationStatus: Completed, Estimated PCD: 2021-10-12
Clinical trial
Phase 1b/2, Multicenter, Open-label, Dose-Expansion Modular Study To Explore the Safety, Tolerability, and Anti-tumor Activity of HER3- DXd Monotherapy and Combinations in Patients With Inoperable Advanced Breast Cancer (ABC) After Progression on T-DXdStatus: Recruiting, Estimated PCD: 2027-09-01
Clinical trial
Biological Medicine for Diffuse Intrinsic Pontine Glioma (DIPG) EradicationStatus: Recruiting, Estimated PCD: 2028-09-01
Clinical trial
Phase I / II Study of Sequential High-dose Chemotherapy With Stem Cell Support in Children Younger Than 5 Years of Age With High-risk MedulloblastomaStatus: Terminated, Estimated PCD: 2020-10-25
Clinical trial
Randomized Phase II Trial Assessing the Inhibitor of Programmed Cell Death Ligand 1 (PD-L1) Immune Checkpoint Atezolizumab in Locally Advanced Cervical CancerStatus: Active (not recruiting), Estimated PCD: 2024-02-26
Clinical trial
Impact of Neoadjuvant Immunotherapy in Early Stage Breast Cancer Before Standard TherapyStatus: Recruiting, Estimated PCD: 2025-02-01
Clinical trial
An Open-Label Multicenter Phase 1b Study of Tolinapant (ASTX660) in Combination With Radiotherapy/Chemoradiotherapy (RT/CRT) in Preoperative Treatment of Patients With Rectum Cancer (PRAAR 1: Preoperative Radiotherapy And ASTX660 in Rectum Cancer)Status: Recruiting, Estimated PCD: 2028-01-01
Clinical trial
Phase II Multicentric Study: Efficacy Evaluation of Neoadjuvant Treatment Associated With Maintenance Therapy by Anti-PD1 Immunotherapy on Disease-free-survival (DFS) in Patients With Resectable Head and Neck Mucosal MelanomaStatus: Recruiting, Estimated PCD: 2026-05-01
Clinical trial
tislelizUMaB in canceR Patients With molEcuLar residuaL DiseaseStatus: Not yet recruiting, Estimated PCD: 2028-05-01
Clinical trial
An International Multicenter Phase II Randomised Trial Evaluating and Comparing Two Intensification Treatment Strategies for Metastatic Neuroblastoma Patients With a Poor Response to Induction ChemotherapyStatus: Terminated, Estimated PCD: 2023-08-28
Clinical trial
Adjuvant Immunotherapy After Salvage Surgery in Head and Neck Squamous Cell Carcinoma : Phase 2 Trial Evaluating the Efficacy and the Toxicity of Nivolumab Alone, and of the Combination Nivolumab and IpilimumabStatus: Recruiting, Estimated PCD: 2026-05-01
Clinical trial
A Phase I Study Evaluating Safety and Efficacy of Hepatic Intra-Arterial Administration of Ipilimumab in Combination With Intra-venous Nivolumab for Advanced Hepatocellular CarcinomaStatus: Recruiting, Estimated PCD: 2022-11-04
Clinical trial
A Window of Opportunity (WoO) Study Evaluating Pembrolizumab With or Without Olaparib in Tertiary Lymphoid Structures (TLS)-Positive Selected Resectable Soft Tissue Sarcoma (STS) Followed by Adjuvant PembrolizumabStatus: Not yet recruiting, Estimated PCD: 2026-09-01
Clinical trial
A Phase II Study to Assess the Efficacy of the Anti-PD-L1 Antibody Atezolizumab (MPDL3280A) Administered With Stereotactic Ablative Radiotherapy (SABR) in Patients With Metastatic TumoursStatus: Active (not recruiting), Estimated PCD: 2022-05-20
Clinical trial
Engineering Immune Organoids to Study Pediatric Cancer (IMMUNE-ORGANOIDS)Status: Recruiting, Estimated PCD: 2028-05-01
Clinical trial
Postoperative Hepatic Arterial Chemotherapy in High-risk Patients as Adjuvant Treatment After Resection of Colorectal Liver Metastases - A Randomized Phase II/III TrialStatus: , Estimated PCD: 2028-05-01
Clinical trial
Short-term Pre-OPerative Durvalumab (MEDI 4736) in Early Small Triple Negative Breast Cancer Patients (POP-Durva)Status: Recruiting, Estimated PCD: 2026-06-01
Clinical trial
Implementing Precision Medicine in cOmmunity HospiTALsStatus: Recruiting, Estimated PCD: 2024-04-15
Clinical trial
Phase 2, Open Label Study of Patritumab Deruxtecan (U3-1402), an Anti-HER3-Antibody Drug Conjugate (ADC), in Patients With Advanced Breast Cancer, With Biomarker Analyses to Characterize Response to TherapyStatus: Recruiting, Estimated PCD: 2024-01-11
Clinical trial
European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory TumorsStatus: Recruiting, Estimated PCD: 2027-08-01
Clinical trial
Phase Ib Study of the Combination of Regorafenib With Conventional Chemotherapy for the Treatment of Newly Diagnosed Patients With Multimetastatic Ewing SarcomaStatus: Recruiting, Estimated PCD: 2026-03-27
Clinical trial
A Prospective Program Aiming at Improving Outcome for Young Adults With Poor-prognosisStatus: Recruiting, Estimated PCD: 2031-02-01
Clinical trial
A Multicenter, Open Label, Phase II Basket Trial Exploring the Efficacy and Safety of the Combination of Rucaparib (PARP Inhibitor) and Atezolizumab (Anti-PD-L1 Antibody) in Patients With DNA Repair-deficient or Platinum-sensitive Solid TumorsStatus: , Estimated PCD: 2024-12-01
Clinical trial
Differentiated Thyroid Cancer: is There a Need for Radioiodine Ablation in Low Risk Patients?Status: Active (not recruiting), Estimated PCD: 2022-04-01
Clinical trial
Maintenance Pembrolizumab at Usual or Low doSE in Non-squamous Lung Cancer: a Non-inferiority StudyStatus: Recruiting, Estimated PCD: 2029-01-01
Clinical trial
Phase Ib Trial Of Pembrolizumab And NintedanibStatus: Recruiting, Estimated PCD: 2025-11-01
Clinical trial
A Phase III Trial of Acetylsalicylic Acid and Atorvastatin in Patients With Castrate-resistant Prostate CancerStatus: Recruiting, Estimated PCD: 2034-03-01
Clinical trial
A Randomized Phase I/II Trial Evaluating the Safety & Efficacy of Intra-Tumoral Ipilimumab in Combination With Intra-venous Nivolumab in Patients With Metastatic MelanomaStatus: Completed, Estimated PCD: 2021-01-01
Clinical trial
An Open-label Phase 1 of Pembrolizumab in Combination With Bevacizumab and Pegylated Liposomal Doxorubicin in Patients With Platinum Resistant Epithelial Ovarian CancerStatus: Active (not recruiting), Estimated PCD: 2021-03-11
Clinical trial
A Phase I Trial Assessing the Safety and Efficacy of an Anti-tumor Immunity Priming Strategy Combining Intratumoral Tilsotolimod, a TLR-9 Agonist, Together With Intratumoral Ipilimumab and Intravenous Nivolumab in Patients With Advanced CancersStatus: Active (not recruiting), Estimated PCD: 2024-02-01
Clinical trial
An Open-label, Multicentric, Phase Ib/II Study to Assess the Safety and Efficacy of AsiDNATM, a DNA Repair Inhibitor, Administered Intravenously in Addition to Niraparib in Patients With Relapsed Platinum Sensitive Ovarian Cancer Already Treated With Niraparib Since at Least 6 MonthsStatus: Recruiting, Estimated PCD: 2023-10-01
Clinical trial
Randomized Phase 2 Trial Of Two Chemotherapy Regimens Plus Or Minus Bevacizumab In Patients With Well Differentiated Pancreatic Neuroendocrine TumorsStatus: Active (not recruiting), Estimated PCD: 2028-12-01
Clinical trial
Pan-lesions SBRT Combined With Lymphocyte Support Through ATRA-driven Blockade of MDSC in Patients With Oligo-metastatic Solid CancerStatus: Recruiting, Estimated PCD: 2026-08-01
Clinical trial
An Open Label Phase II Basket Trial Exploring the Efficacy and Safety of the Combination of Niraparib and Dostarlimab in Patients With DNA Repair-deficient or Platinum-sensitive Solid TumorsStatus: , Estimated PCD: 2024-12-01
Clinical trial
High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN)Status: Recruiting, Estimated PCD: 2026-11-01
Clinical trial
A Study of Patient Preference Between ODM-201 and Enzalutamide in Men With Metastatic Castrate-resistant Prostate CancerStatus: Active (not recruiting), Estimated PCD: 2022-01-31
Clinical trial
Implementing Precision Medicine in cOmmunity HospiTALsStatus: Recruiting, Estimated PCD: 2024-11-15